CA
KDNY

CoreCap Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

CoreCap Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$16.8K Buy
+640
New +$14.2K ﹤0.01% 1357

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

CoreCap Advisors's KDNY Position: Q4 2022 in Review

CoreCap Advisors opened a new position in Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2022: 640 shares worth $16.8K. The stake represents ﹤0.01% of the portfolio and ranks #1357 among its holdings.

155 funds tracked by Wall St. Rank hold KDNY as of Q4 2022.

  • CoreCap Advisors held 640 shares of Chinook Therapeutics, Inc. Common Stock worth $16.8K as of Q4 2022.
  • Chinook Therapeutics, Inc. Common Stock was a new CoreCap Advisors position in Q4 2022.
  • Chinook Therapeutics, Inc. Common Stock made up ﹤0.01% of CoreCap Advisors's portfolio in Q4 2022, its #1357 holding.
  • 155 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2022.

Based on CoreCap Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.